Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease? Sarah MarmolMatthew FeldmanJason Margolesky Current Opinion 14 October 2021 Pages: 1141 - 1152
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions Joshua T. Kantrowitz Leading Article 15 October 2021 Pages: 1153 - 1161
Tranexamic Acid for Adult Patients with Spontaneous Intracerebral Hemorrhage: A Systematic Review with Meta-analysis Xing WangLu MaChao You Systematic Review 18 October 2021 Pages: 1163 - 1172
Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology Fabian SzepanowskiClemens WarnkeMark Stettner Review Article Open access 16 October 2021 Pages: 1173 - 1188
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia John M. KaneJoseph P. McEvoyPierre-Michel Llorca Review Article Open access 11 October 2021 Pages: 1189 - 1205
Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children with Intractable Epilepsy: A Prospective Open-Label Study Kerstin A. KlotzDaniel GrobJulia Jacobs Original Research Article Open access 22 October 2021 Pages: 1207 - 1215
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts Sifat SharminMathilde LefortDanish Multiple Sclerosis Registry, OFSEP and the MSBase investigators Original Research Article 18 September 2021 Pages: 1217 - 1232